1,720,962 research outputs found
Bone tissue: hormonal regulating systems, growth factors and remodeling as a target for therapeutic agents in osteoporosis
Full text linkBone regulating systems have received growing attention in recent years. Regulation of skeletal pathophysiology and modulation of osteoblast, osteoclast and osteocyte activity by hormones, cytokines, and growth factors are not only important features of bone biology, but also a target for old and new osteoporosis therapies.
Molecules such as selective estrogen receptor modulators (SERMs, e.g. raloxifene and bazedoxifene), denosumab, or bisphosphonates may exert their effects through modulation of estrogen receptor, RANKL and osteoclast activity, respectively. Knowledge of the regulating systems is also the basis for developing future therapy. This review shows regulating systems as a basis for current and future therapies in the field of osteoporosi
Clinical trial of a monophasic estroprogestin oral formulation containing 20 mcg ethinyl estradiol and 75 mcg gestodene,
No full textEffects on body weight and body composition of a low-dose oral estroprogestin containing ethinyl estradiol 20 mu g plus levonorgestrel 100 mu g
No full textWeight gain is a common problem reported by users of estroprogestins (EPs) and is a frequent reason for EP discontinuation, even if this problem is not confirmed in several clinical studies. We studied the impact of a EP containing ethinyl estradiol (EE) 20 mu g plus levonorgestrel (LNG) 100 mu g on body weight (BW) and body composition in 47 treated women and 31 women as controls. Also, we studied the effect of this association on metabolic parameters (glycemia, lipid profile). EE20/LNG100 had no significant impact on body weight, body composition (fat mass, fat-free mass, total body water, intracellular water, extracellular water) or metabolic profile in comparison with no treatment. Thus, the use of EE20/LNG100 showed no impact on metabolic parameters, body weight and body composition. This could be important not only for the safety profile of this combination, but also in increasing patient compliance
Effects on body weight and body composition of a low-dose oral estroprogestin containing ethinyl estradiol 20 mu g plus levonorgestrel 100 mu g
No full textWeight gain is a common problem reported by users of estroprogestins (EPs) and is a frequent reason for EP
discontinuation, even if this problem is not confirmed in several clinical studies. We studied the impact of a
EP containing ethinyl estradiol (EE) 20 mg plus levonorgestrel (LNG) 100 mg on body weight (BW) and body
composition in 47 treated women and 31 women as controls. Also, we studied the effect of this association on metabolic
parameters (glycemia, lipid profile). EE20/LNG100 had no significant impact on body weight, body composition (fat
mass, fat-free mass, total body water, intracellular water, extracellular water) or metabolic profile in comparison with no
treatment. Thus, the use of EE20/LNG100 showed no impact on metabolic parameters, body weight and body
composition. This could be important not only for the safety profile of this combination, but also in increasing patient
compliance
Menopause and quality of life: Effects of tibolone (Article) [Menopausa e qualità della vita: Effetti del tibolone]
No full textMenopause is associated with symptoms caused by estrogen deficiency. These symptoms may have a negative impact on overall quality of life of a menopausal woman. Hot flashes, sweating, sleep disturbances and vaginal dryness are common symptoms. Decreased sexual desire is related to both estrogen and androgen deficiency. Climacteric syndrome includes also mood disturbances. Hormonal Replacement Therapy (HRT) improves many of these symptoms. Tibolone, through its estrogenic and androgenic activities, is able to improve significantly these problems, including decreased libido, obtaining a positive effect on overall quality of life in menopause
Duloxetine in the treatment of urinary incontinence in women
No full textUrinary incontinence is a disease able to decrease the quality of life of affected women. It shows a prevalence of about 35% among adult women. Pharmacological treatment can be used when pelvic floor muscle training has failed or when it could be better to postpone or avoid surgery. Duloxetine, a selective serotonin and noradrenaline reuptake inhibitor (SNRI), can act effectively in treating stress urinary incontinence
Effects of two estroprogestins containing ethynilestradiol 30g and drospirenone 3mg and ethynilestradiol 30g and chlormadinone 2mg on skin and hormonal hyperandrogenic manifestations
No full textHyperandrogenic manifestation in women, such as seborrhea, acne and increased hair growth are common reasons of psychological distress. Skin appearance is very important for young women. This study evaluated the hormonal and skin effects of two estroprogestins (EPs) containing ethinyl-estradiol (EE) 30g associated with drospirenone (DRSP) 3mg or chlormadinone acetate (CMA) 2mg, respectively. Fifty-five women with signs and symptoms of hyperandrogenism (seborrhea, acne and increased hair growth) were enrolled in the study; randomly, 30 women were treated with EE 30g + DRSP 3mg and 25 with EE 30g + CMA 2mg. Follicle-stimulating hormone (FSH), luteinising hormone (LH), 17-hydroxyprogesterone (17OHP), androstenedione (A), testosterone (T), dehydroepiandrosterone sulfate (DHEAS), sex hormone binding globulin (SHBG) and free androgen index (T100/SHBG, FAI) were assessed at baseline, and after 3 and 6 months of treatment with EPs. Effects on seborrhea, acne and increased hair growth (as Ferriman-Gallwey score) were also evaluated at the same time points. Finally, skin hydration, transepidermal water loss (TEWL) and skin homogeneity were studied with non-invasive technique during the study. Treatment for 6 months with both EPs decreased significantly the circulating androgen levels (A, T, DHEAS) and FAI, and increased SHBG levels; also skin pattern was improved. EP containing EE and DRSP was better than EP containing EE and CMA as for skin changes, as seborrhea, acne, increased hair, hydration, homogeneity and overall quality of the skin; moreover, hormonal changes (as FAI) under therapy were more pronounced with EE/DRSP than EE/CMA. These effects may be considered in EP choice and could be important in improving patient's compliance and quality of life in hyperandrogenic women
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Body composition and androgen pattern in the early period of postmenopause
No full textBody composition is related to age, genetic factors, and hormonal patterns throughout life, Peak bone mass seems to be an important protective factor against osteoporosis, although diet and life-style (smoking, physical activity) are able to influence bone mass. While it is well known that estrogens exert a protective action against bone loss in postmenopausal women, the role of androgens is still not clear. Twenty-five women in the early postmenopausal period (age: 52.8 +/- 5.1 years) were measured by dual-energy x-ray absorptiometry (DXA) to assess the relationship between body composition (fat mass and lean mass), bone mineral content (BMC), bone mineral density (BMD) and androgen pattern. Waist/hip ratio was used to divide the study population in three groups: gynecoid (gluteo-femural fat distribution), android abdominal fat distribution), and intermediate. In all subjects an inverse significant correlations between estradiol and fat mass was found. In the abdominal fat distribution group significant correlations between estradiol and weight (inversely correlated), androstenedione and BMD, learn mass an BMC were found. The data show the important role of androgens (androstenedione, particularly) and lean body mass on the BMD and BMC, respectively, in the early period of postmenopause
- …
